<DOC>
	<DOCNO>NCT00202059</DOCNO>
	<brief_summary>The purpose study evaluate effect zoledronic acid physical activity prevent bone loss woman age 40 - 55 receive chemotherapy breast cancer . The primary objective compare percent change lumbar spine bone mineral density ( BMD ) baseline 12 month woman randomize either : Group A ) intravenous zoledronic acid , oral calcium carbonate , vitamin D , Group B ) prescribe physical activity program , oral calcium carbonate vitamin D .</brief_summary>
	<brief_title>Effects Zometa Physical Activity Bone Density Women Receiving Chemotherapy Breast Cancer</brief_title>
	<detailed_description>Background : Breast cancer diagnosis account 32 % new cancer case US woman , approximately 211,300 woman diagnosed 2003 . The majority woman receive adjuvant chemotherapy , may lead chemotherapy-induced menopause ( CIM ) premenopausal woman . CIM often lead accelerated bone loss , osteopenia , eventual osteoporosis . Purpose : The purpose study evaluate effect zoledronic acid physical activity prevent bone loss woman age 40 - 55 receive chemotherapy breast cancer . The primary objective compare percent change lumbar spine bone mineral density ( BMD ) baseline 12 month woman randomize either : Group A ) intravenous zoledronic acid , oral calcium carbonate , vitamin D , Group B ) prescribe physical activity program , oral calcium carbonate vitamin D. Secondary objective compare percent change group total hip BMD , incidence vertebral fracture , fatigue , functional status , cancer-related symptom two group . Methods : Seventy-two woman enrol randomized one two treatment group . For participant randomize Group A , intravenous zoledronic acid give every 3 month 12 month study period , along 2 tablet calcium carbonate ( 600 mg ) /vitamin D ( 200 IU ) daily . For participant randomize Group B , physical activity intervention design improve BMD prescribed administer occupational rehabilitation department . Group B participant also take 2 tablet calcium carbonate ( 600 mg ) /vitamin D ( 200 IU ) daily . BMD measurement lumbar spine hip , AP lateral X-ray do baseline 12 month enrollment study , use dual energy X-ray absorptiometry ( DXA ) . Serum bone-specific alkaline phosphotase , N-telopeptide urine test conduct baseline 12 month evaluate bone resorption activity . Other measure assess via questionnaire include fatigue ( Schwartz Cancer Fatigue Scale ) , functional status ( SF-36 ) , 4-day food record , cancer-related symptom ( MD Anderson Symptom Inventory ) . Analysis : Results analyze intent-to-treat basis . Descriptive statistic use analyze demographic data , tumor information , dietary information baseline BMD . Differences baseline mean analyzed t-tests . The percent change BMD two group analyze analysis covariance ( ANCOVA ) . Differences measure analyze t-tests . Results : Results study use determine zoledronic acid physical activity affect BMD young woman receive chemotherapy breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women Stage I II breast cancer Ages 40 55 Pre perimenopausal Within 1 month begin adjuvant neoadjuvant chemotherapy Baseline lumbar spine total hip BMD &gt; 2.0 SD Able read write English Signed consent form Previous treatment bisphosphonates Laboratory evidence renal disease Previous TRAM flap reconstructive surgery Positive pregnancy test Mental illness precludes patient give informed consent Laboratory evidence hepatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Bone mineral density</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>